^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

BAP1 mutation

i
Other names: BAP1, BRCA1 Associated Protein 1, BRCA1 Associated Protein-1 (Ubiquitin Carboxy-Terminal Hydrolase), Ubiquitin Carboxyl-Terminal Hydrolase BAP1, Cerebral Protein 6, Ubiquitin Carboxy-Terminal Hydrolase, BRCA1-Associated Protein 1, Cerebral Protein-13, HUCEP-13, KIAA0272, Hucep-6, UCHL2
Entrez ID:
Related biomarkers:
Phase N/A
National Cancer Institute (NCI)
Recruiting
Last update posted :
05/14/2024
Initiation :
03/13/2019
Primary completion :
07/06/2026
Completion :
07/05/2027
TP53 • BAP1
|
TP53 mutation • BAP1 mutation
Phase 1/2
Haihe Biopharma Co., Ltd.
Recruiting
Last update posted :
05/09/2024
Initiation :
09/08/2020
Primary completion :
12/31/2025
Completion :
12/31/2025
ARID1A • BAP1
|
ARID1A mutation • BAP1 mutation • EZH2 mutation • SMARCA4 mutation
|
HH2853
Phase N/A
National Cancer Institute (NCI)
Recruiting
Last update posted :
04/17/2024
Initiation :
03/30/2021
Primary completion :
06/30/2038
Completion :
06/30/2038
BAP1
|
BAP1 mutation
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
04/17/2024
Initiation :
01/31/2024
Primary completion :
12/01/2025
Completion :
12/01/2026
BAP1
|
BAP1 mutation
|
Inqovi (decitabine/cedazuridine)
Phase N/A
Massive Bio, Inc.
Recruiting
Last update posted :
03/15/2024
Initiation :
01/01/2018
Primary completion :
12/01/2026
Completion :
06/01/2027
EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703
|
HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation
Phase 2
Massachusetts General Hospital
Recruiting
Last update posted :
03/11/2024
Initiation :
04/05/2022
Primary completion :
12/01/2024
Completion :
12/01/2026
BRCA1 • BRCA2 • HRD • BAP1 • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • BARD1 • NBN • RAD54L • XRCC2 • RAD54B • XRCC3
|
BRCA1 mutation • HRD • ATM mutation • PALB2 mutation • BAP1 mutation • BRIP1 mutation • HRD + BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD50 mutation • RAD51B mutation • BARD1 mutation • MRE11A mutation • RAD54L mutation • NBN mutation • HRD signature
|
Zejula (niraparib)
Phase N/A
Nantes University Hospital
Active, not recruiting
Last update posted :
02/26/2024
Initiation :
02/23/2022
Primary completion :
02/01/2026
Completion :
02/01/2026
BAP1 • DICER1
|
BAP1 mutation
Phase 2
Asan Medical Center
Recruiting
Last update posted :
01/17/2024
Initiation :
04/01/2022
Primary completion :
12/30/2024
Completion :
12/30/2025
BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1
|
ATM mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • FANCA mutation • RAD50 mutation • BARD1 mutation • BLM mutation • NBN mutation
|
Lynparza (olaparib) • Imfinzi (durvalumab)
Phase N/A
Mohamed Abdel-Rahman
Recruiting
Last update posted :
10/25/2023
Initiation :
03/03/2015
Primary completion :
07/01/2026
Completion :
07/01/2026
BAP1
|
BAP1 mutation
Phase 2
University of Chicago
Recruiting
Last update posted :
04/28/2023
Initiation :
02/19/2021
Primary completion :
10/15/2024
Completion :
10/15/2025
BAP1
|
BAP1 mutation
|
Lynparza (olaparib) • cisplatin
Phase 2
California Pacific Medical Center Research Inst...
Recruiting
Last update posted :
12/06/2022
Initiation :
03/03/2021
Primary completion :
06/30/2023
Completion :
12/31/2024
BRAF • BRCA1 • BRCA2 • ARID1A • BAP1 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD50 • ARID2 • BARD1 • FANCD2 • RAD54B
|
BRCA2 mutation • BRCA1 mutation • BRAF mutation • BRAF V600 • ATM mutation • ARID1A mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • FANCA mutation • RAD50 mutation • BARD1 mutation
|
Keytruda (pembrolizumab) • Lynparza (olaparib)
Phase 2
Fudan University
Recruiting
Last update posted :
06/30/2022
Initiation :
09/14/2020
Primary completion :
11/20/2022
Completion :
12/28/2022
HER-2 • BRCA1 • BRCA2 • PTEN • BAP1 • CDK12 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • FANCF • WRN • FANCM • FANCD2 • FANCE • FANCC
|
HER-2 positive • BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative • ATM mutation • PALB2 mutation • CDK12 mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • HR positive + HER-2 negative • RAD50 mutation • BARD1 mutation • BLM mutation • CHEK1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation • CHEK1 expression
|
Herceptin (trastuzumab) • cisplatin • Zejula (niraparib) • Puyouheng (pucotenlimab)
Phase 2
California Pacific Medical Center Research Inst...
Recruiting
Last update posted :
10/22/2021
Initiation :
03/20/2019
Primary completion :
02/01/2022
Completion :
02/01/2023
BRAF • BRCA1 • BRCA2 • ARID1A • BAP1 • ATRX • BRCA • CHEK2 • RAD51 • BRIP1 • RAD50 • ARID2 • BARD1 • FANCD2 • RAD54B
|
BRCA2 mutation • ATM mutation • ARID1A mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • RAD50 mutation • BARD1 mutation
|
Zejula (niraparib)
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
04/09/2021
Initiation :
07/11/2018
Primary completion :
12/04/2019
Completion :
10/21/2020
BAP1 • BRCA
|
BAP1 mutation
|
Lynparza (olaparib)
Phase 2
Epizyme, Inc.
Completed
Last update posted :
04/09/2021
Initiation :
07/01/2016
Primary completion :
06/01/2018
Completion :
05/01/2019
BAP1
|
BAP1 mutation
|
Tazverik (tazemetostat)
Phase N/A
Amy C Schefler, MD
Active, not recruiting
Last update posted :
03/26/2021
Initiation :
07/01/2013
Primary completion :
01/01/2022
Completion :
01/01/2022
BAP1
|
BAP1 mutation
Phase 1
Beijing Cancer Hospital
Not yet recruiting
Last update posted :
02/22/2021
Initiation :
04/01/2021
Primary completion :
11/01/2021
Completion :
02/28/2023
HER-2 • BRCA1 • BRCA2 • HRD • BAP1 • CHEK2 • RAD51 • FANCA • BRIP1
|
BRCA1 mutation • HER-2 negative • ATM mutation • PALB2 mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • FANCA mutation • RAD51 mutation
|
Focus V (anlotinib) • Zejula (niraparib)
Phase N/A
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
07/01/2020
Initiation :
01/01/2013
Primary completion :
06/30/2020
Completion :
06/30/2020
BAP1
|
BAP1 mutation
Phase N/A
Hospices Civils de Lyon
Completed
Last update posted :
07/26/2016
Initiation :
05/01/2013
Primary completion :
01/01/2016
Completion :
01/01/2016
BAP1
|
BAP1 mutation